Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response. [PDF]
Ferreira APS +11 more
europepmc +1 more source
Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells. [PDF]
Kamyabi R +3 more
europepmc +1 more source
The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. [PDF]
Cleverley TL +7 more
europepmc +1 more source
Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. [PDF]
Ferreira APS +11 more
europepmc +1 more source
Use of Imatinib in the Prevention of Heterotopic Ossification [PDF]
Background: Heterotopic ossification (HO) is a common complication following orthopedic and trauma surgery, which may have substantial negative effects on the postoperative outcome. Angiogenesis appears to play a critical role in heterotopic ossification.
Lane, Joseph +5 more
core
Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. [PDF]
PLOS ONE Editors.
europepmc +1 more source
Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis. [PDF]
Perkins ME +3 more
europepmc +1 more source
A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease.
Ol'ga Veniaminovna Stakhina +7 more
doaj
Imatinib Mesylate Induces Necroptotic Cell Death and Impairs Autophagic Flux in Human Cardiac Progenitor Cells. [PDF]
Walmsley R +4 more
europepmc +1 more source
Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters. [PDF]
Omran MM +5 more
europepmc +1 more source

